Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 26, 2007

Abraxis and the California NanoSystems Institute to Jointly Pursue Nanobiotechnology

  • Abraxis BioScience and the California NanoSystems Institute (CNSI) at UCLA are partnering to advance research in nanobiotechnology.

    Abraxis will contribute $10 million over 10 years for projects in the new CNSI building at UCLA, or the Abraxis/CNSI Research Collaboration Lab space.

    Abraxis also became CNSI’s first partner in the area of pharmaceuticals and biotechnology through the institute's Partners Program. The collaboration provides CNSI and Abraxis researchers the opportunity to jointly pursue innovative approaches to the diagnosis and treatment of life-threatening diseases.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »